Understanding Shingles and Why Vaccination Matters
Shingles is a viral infection caused by the varicella-zoster virus, the same virus that causes chickenpox. After a person recovers from chickenpox, the virus remains dormant in nerve tissue near the spinal cord and brain. Later in life—sometimes decades later—the virus can reactivate and cause shingles. This reactivation typically occurs when the immune system becomes weakened due to age, stress, certain medications, or other health conditions.
Free Guide to Florida Driver's License Appointment Planning →
The symptoms of shingles include a painful rash that usually appears on one side of the body, often in a band-like pattern. The rash typically progresses through stages: red patches appear first, followed by fluid-filled blisters, and eventually crusting and healing. Pain associated with shingles can range from mild burning sensations to severe throbbing pain that interferes with daily activities. Some people experience itching, tingling, or numbness in the affected area.
According to the Centers for Disease Control and Prevention (CDC), about 1 million cases of shingles occur in the United States each year. Approximately 1 in 3 Americans will develop shingles during their lifetime. The risk increases significantly with age—about half of all shingles cases occur in people aged 60 and older. Even in people who recover from the acute infection, long-term complications can develop, including postherpetic neuralgia (PHN), a condition where pain persists for months or even years after the rash heals.
Vaccination offers a way to reduce the risk of developing shingles and its complications. Two vaccines are currently authorized in the United States: Shingrix (recombinant zoster vaccine) and Zostavax (live attenuated varicella-zoster vaccine). Shingrix has demonstrated greater effectiveness in clinical studies, showing about 90% effectiveness in preventing shingles in people aged 60 and older, with effectiveness remaining above 85% in adults aged 70 and older after four years of follow-up.
Practical Takeaway: Understanding that shingles results from reactivation of chickenpox virus and can cause significant pain and complications helps explain why public health organizations recommend vaccination, particularly for older adults and those with weakened immune systems.
The Shingrix Vaccine: Current Recommendation and Schedule
Shingrix is the preferred shingles vaccine currently recommended by the CDC's Advisory Committee on Immunization Practices (ACIP). This is a recombinant subunit vaccine, meaning it contains a single component of the varicella-zoster virus rather than a live virus. The vaccine was approved by the U.S. Food and Drug Administration (FDA) in 2017, and recommendations have evolved since then based on ongoing research and clinical experience.
How to Contact Waste Connections Customer Service →
The standard Shingrix schedule consists of two doses. The second dose should be administered 2 to 6 months after the first dose. Research indicates that spacing the doses further apart within this window does not reduce the vaccine's effectiveness, so there is flexibility in scheduling based on individual circumstances and healthcare availability. Both doses are necessary for optimal protection—completing the series is important for achieving the high effectiveness rates demonstrated in clinical trials.
For most adults aged 50 and older without contraindications, Shingrix is recommended regardless of whether they recall having chickenpox or a previous shingles infection. People who previously received Zostavax may also receive Shingrix. Current guidelines suggest waiting at least 12 months after receiving Zostavax before receiving Shingrix, though some healthcare providers may administer Shingrix sooner if a person requests it or if access to the vaccine is limited. People with a current shingles infection should not receive the vaccine until the rash has healed.
The vaccine is administered as an intramuscular injection, typically in the upper arm. No special preparation is needed before vaccination. Common side effects include soreness, redness, or swelling at the injection site, as well as fatigue, muscle aches, or headache. These side effects are generally mild to moderate and resolve within 2 to 3 days. Serious side effects are rare. The vaccine contains no live virus, so it cannot cause shingles.
Practical Takeaway: Shingrix requires two doses spaced 2 to 6 months apart, and most adults aged 50 and older should receive it regardless of chickenpox history, with flexibility in scheduling the doses according to individual needs and circumstances.
Age-Based Vaccine Recommendations and Special Populations
The CDC recommends Shingrix for all adults aged 50 and older, with some exceptions for people with certain medical conditions or those taking specific medications. This age-based recommendation differs from earlier guidance that focused on adults aged 60 and older. The expansion to age 50 reflects the vaccine's high effectiveness and the potential for significant complications from shingles even in younger older adults.
Get Your Free Texas DPS Appointment Preparation Guide →
For adults aged 19 to 49 years old, Shingrix is recommended in certain circumstances. These include people with weakened immune systems due to conditions such as HIV infection, organ transplantation, or chronic corticosteroid use. People with autoimmune conditions like rheumatoid arthritis or inflammatory bowel disease may also be candidates for vaccination, particularly if they are taking immunosuppressive medications. Healthcare providers can determine whether vaccination is appropriate based on individual health status.
Pregnant women should not receive Shingrix. However, breastfeeding is not a contraindication to vaccination. Women of childbearing age who are not currently pregnant and do not plan to become pregnant in the next 4 weeks may receive the vaccine. Men and women who plan to have children in the future may be vaccinated without concern, as the vaccine will not affect future fertility or pregnancy outcomes.
People with severe allergies to any component of the vaccine or who have experienced severe allergic reactions to a previous dose should not receive Shingrix. The vaccine contains gelatin and other components, so people with known allergies to these substances should inform their healthcare provider before vaccination. People with moderate to severe acute illness should postpone vaccination until their illness improves, though mild illnesses do not require delaying vaccination.
Special consideration applies to people who have recently received other vaccines. Shingrix may be given at the same visit as other inactivated vaccines at different injection sites or at any time before or after other inactivated vaccines. Live vaccines must be given either on the same day as Shingrix or at least 4 weeks apart. Healthcare providers can advise on vaccine spacing if multiple vaccines are needed.
Practical Takeaway: While adults aged 50 and older are the main recommendation group, younger adults with weakened immune systems may also benefit from Shingrix, and healthcare providers can determine individual recommendations based on personal health circumstances and age.
Zostavax and Transition to Shingrix
Zostavax was the first varicella-zoster vaccine licensed in the United States, approved in 2006. It is a live attenuated vaccine, meaning it contains a weakened form of the varicella-zoster virus. For many years, Zostavax was the standard recommendation for adults aged 60 and older. However, since Shingrix was approved and shown to be more effective, the CDC's preference has shifted to Shingrix for new vaccinations.
Learn About Visiting the Parkland Washington DMV →
As of January 2018, the CDC no longer recommends Zostavax for routine use in the United States. This change reflects the superior effectiveness of Shingrix—approximately 90% effectiveness compared to about 50% effectiveness for Zostavax. Additionally, Shingrix protection remains strong over time, whereas Zostavax effectiveness wanes more rapidly. The effectiveness of Shingrix in preventing postherpetic neuralgia, the most serious complication of shingles, is also higher than with Zostavax.
People who previously received Zostavax do not need to wait an extended period before receiving Shingrix. Current guidance suggests waiting at least 12 months after Zostavax before receiving Shingrix. However, the CDC notes that the vaccine series may be given sooner if a person prefers or if access to Zostavax is no longer available. Some healthcare settings may administer Shingrix immediately or after just a few weeks if the person requests it or circumstances warrant.
Zostavax cannot be given to people with weakened immune systems due to conditions like HIV infection,